UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37534 PLANET FITNESS, INC. (Exact name of Registrant as specified in its Charter) Delaware 38-3942097 (State or Other Jurisdiction of In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year enDdecdember 31, 2025 Energy Recovery, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification No.) Delaware 01-0616867 1717 Doolittle Drive San Leand,rCoalifornia94577 (Address of Principal Executive Offices) (Zip Code) ☐ TRANSITI ...

Financial Performance - Arcus reported revenues of $33 million for Q4 2025, a decrease from $36 million in Q4 2024, with $23 million from Gilead collaboration and $7 million from Taiho's option exercise[17]. - The net loss for Q4 2025 was $106 million, compared to a net loss of $94 million in Q4 2024[17]. - Total revenues for Q4 2025 were $33 million, a decrease of 8.3% from $36 million in Q4 2024[22]. - Basic and diluted net loss per share improved slightly to $(0.89) in Q4 2025 from $(1.03) in Q4 2024[22]. - GAAP revenue for the full year 2026 is projected to be between $45 million and $55 million[17]. Research and Development - Research and Development (R&D) expenses increased to $121 million in Q4 2025 from $111 million in Q4 2024, driven by higher late-stage development costs[17]. - Arcus anticipates a decrease in R&D expenses for the full year 2026 compared to 2025, influenced by the results of the futility analysis of the STAR-121 study[17]. - Research and development expenses for the year ended December 31, 2025, were $523 million, up from $448 million in 2024, indicating a continued focus on innovation[22]. - The Phase 3 PEAK-1 study for casdatifan is currently enrolling globally, targeting a peak sales opportunity exceeding $5 billion in the IO-experienced and first-line settings[3]. - Casdatifan demonstrated a median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% in late-line kidney cancer[6]. - Arcus plans to initiate a Phase 3 study for casdatifan in a TKI-free combination by the end of 2026, focusing on first-line metastatic settings[6]. - The company expects to advance its first inflammation program, a potential oral MRGPRX2 antagonist, into clinical development in 2026[12]. Financial Position - Arcus has $1.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, up from $992 million in 2024, providing a cash runway until at least the second half of 2028[17]. - Cash, cash equivalents, and marketable securities increased to $1,010 million as of December 31, 2025, compared to $992 million a year earlier[24]. - Total assets decreased to $1,139 million in 2025 from $1,150 million in 2024[24]. - Total liabilities decreased significantly from $665 million in 2024 to $508 million in 2025, indicating improved financial health[24]. - Total stockholders' equity increased to $631 million in 2025, up from $485 million in 2024, reflecting a strong capital position[24]. Operating Expenses - Total operating expenses rose to $147 million in Q4 2025, up from $139 million in Q4 2024, primarily driven by increased research and development costs[22].

Financial Performance - Fourth quarter revenue reached $225.4 million, representing a 23% year-over-year increase, contributing to a full-year revenue of $836.6 million, up 22% year-over-year [2]. - GAAP net income for Q4 was $14.0 million, or $0.19 per diluted share, a decrease of 64% compared to the previous year, while full-year net income was $48.7 million, or $0.64 per diluted share [5]. - Adjusted EBITDA for Q4 was $36.7 million, a 19% increase year-over-year, while full-year adjusted EBITDA reached $145.0 million [5]. - Net income for the year ended December 31, 2025, was $48.7 million, a 60% increase from $30.4 million in 2024 [21]. - Non-GAAP operating income for the year ended December 31, 2025, was $96.0 million, a 102% increase from $47.6 million in 2024 [30]. - Adjusted EBITDA for the year ended December 31, 2025, reached $145.0 million, a 35% increase from $107.9 million in 2024 [30]. - The company expects 2026 annual GAAP operating income to be in the range of $72-$89 million and non-GAAP operating income to be in the range of $95-$110 million [33]. - GAAP operating income is projected to be between $22 million and $27 million for the first quarter of 2026 [35]. - Non-GAAP operating income is expected to range from $28 million to $32 million for the first quarter of 2026 [35]. - Full year 2026 GAAP operating income is anticipated to be between $72 million and $89 million [35]. - Full year 2026 non-GAAP operating income is expected to be in the range of $95 million to $110 million [35]. Revenue Breakdown - Loans revenue surged 141% year-over-year to $42.3 million, driven by growth in personal and mortgage loans [6]. - Insurance revenue increased by 13% year-over-year to $81.2 million, primarily due to expanded budgets for auto insurance products [6]. - Credit card revenue decreased by 24% year-over-year to $26.5 million, attributed to ongoing challenges in organic search traffic [6]. - SMB products revenue fell 12% year-over-year to $22.5 million, also impacted by organic search traffic headwinds [6]. - Revenue is expected to be in the range of $224-$232 million, representing a 9% year-over-year increase at the midpoint [36]. Cash and Investments - Cash and cash equivalents increased by 48% year-over-year to $98.3 million [7]. - The company reported a net increase in cash and cash equivalents of $32.0 million for the year ended December 31, 2025 [21]. - Adjusted free cash flow for the year ended December 31, 2025, was $117.8 million, compared to $48.5 million in 2024, indicating a significant increase [32]. - Capitalized software development costs for the year ended December 31, 2025, were $16.9 million, down from $20.7 million in 2024 [32]. Operational Metrics - The operating income margin for the year ended December 31, 2025, was 8%, compared to 1% in 2024 [30]. - The company reported a non-GAAP operating income margin of 11% for the year ended December 31, 2025, up from 7% in 2024 [30]. Future Outlook - The company is unable to provide a quantitative reconciliation of forecasted GAAP net income to forecasted adjusted EBITDA due to uncertainties in certain reconciling items [34]. - The company faces significant risks and uncertainties that may cause actual results to differ materially from forward-looking statements [39]. - The company aims to grow traffic, engagement, and monetization on its platform while expanding within existing and new verticals [41]. - The company is focused on developing scalable technology and enhancing user engagement through personalized guidance [41]. Shareholder Returns - The company announced a $100 million increase in its share repurchase program, bringing the total authorized amount to $225 million [14]. Reporting Changes - Effective Q1 2026, revenue will be reported by user groups: Consumer and SMB, aligning with management's evaluation of financial performance [10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Inco ...

Revenue Projections - Veracyte expects total revenue for Q4 2025 to be between $138 million and $140 million, with testing revenue between $134 million and $136 million[5]. - For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, with testing revenue between $491 million and $493 million[5]. Testing Volume - The company anticipates testing volume of approximately 45,500 tests for Q4 2025[5]. - The projected testing volume for the full year 2025 is approximately 169,700 tests[5]. Financial Metrics - Veracyte expects an adjusted EBITDA margin of greater than 25% for the full year 2025[5]. - The company is unable to provide an estimate of net income margin for the full year 2025 due to the unavailability of reliable estimates[6]. - Key components affecting net income margin may include stock-based compensation expenses and acquisition-related expenses[6]. Financial Reporting - The preliminary financial results are subject to completion of financial closing procedures and audit adjustments[6]. - Veracyte's audited financial statements for the full year ended December 31, 2025, are not yet available[6]. - The press release regarding these results was issued on January 11, 2026[5].

CONTACT: Brendon Frey Brendon.frey@icrinc.com HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS Fourth Quarter Revenue Relatively Flat at $212.9 Million Fourth Quarter Gross Margin Expands 220 Basis Points Fourth Quarter Operating Profit Grows 8.0% to $25.4 Million Selling, general and administrative expenses (SG&A) increased to $34.7 million compared to $32.1 million. The increase was primarily driven by higher performance-based compensation expense related to improv ...

Revenue Growth - Fourth quarter revenue reached $1.28 billion, reflecting a 30% year-over-year growth[1] - Product revenue for the fourth quarter was $1.23 billion, also up 30% year-over-year, with remaining performance obligations totaling $9.77 billion, a 42% increase year-over-year[2] - For fiscal 2027, product revenue guidance is set between $1,262 million and $1,267 million for Q1, and $5,660 million for the full year, both reflecting a 27% year-over-year growth[6] - Full-year product revenue for fiscal 2026 was $4,472.3 million, a 29% increase year-over-year, with a non-GAAP operating income of $489.7 million[8] - Product revenue for the fiscal year ended January 31, 2026, was $4,683,946,000, representing a 29.3% increase from $3,626,396,000 in the previous year[25] - Product revenue for Q1 2026 reached $1,226.6 million, a 30% increase year-over-year from $943.3 million in Q1 2025[31] - Total revenue for the twelve months ended January 31, 2026, was $4,683.9 million, up 29% from $3,626.4 million in the previous year[31] - Year-over-year growth for total revenue was 30% for Q1 2026, compared to 27% for Q1 2025[31] Customer Metrics - The net revenue retention rate stood at 125%, indicating strong customer engagement and expansion[4] - Snowflake added 740 net new customers in the quarter, marking a 40% year-over-year growth, with 733 customers now spending over $1 million annually[4] - The company served 790 of the Forbes Global 2000 customers, indicating a 5% year-over-year growth in enterprise adoption[5] - The number of customers with trailing 12-month product revenue greater than $1 million is a key metric, reflecting the company's ability to attract high-value clients[18] - User data metrics show a significant increase in engagement, supporting future revenue growth projections[1] Financial Performance - Non-GAAP product gross profit margin for Q4 was 75%, while operating income was reported at $139.2 million, representing an 11% margin[7] - Operating loss for the quarter was $318,159,000, a slight improvement from a loss of $386,678,000 in the same quarter last year[25] - Net loss attributable to Snowflake Inc. for the fiscal year was $1,331,616,000, compared to $1,285,640,000 in the previous year, indicating ongoing investment in growth despite losses[25] - The company reported interest income of $42,445,000 for the quarter, down from $56,310,000 in the previous year, reflecting changes in market conditions[25] - Net loss for the three months ended January 31, 2026, was $309,550 thousand, a slight improvement from a net loss of $325,724 thousand in the same period last year[29] - Non-GAAP operating margin was reported at 11%, down from 12.7% in the previous year[1] - The company reported a net increase in cash, cash equivalents, and restricted cash of $879,672 thousand for the current quarter, compared to $532,440 thousand in the same quarter last year[29] Expenses and Investments - Total operating expenses reached $1.175 billion, reflecting a 22% increase year-over-year[1] - Research and development expenses increased to $511 million, representing a 38% increase year-over-year[1] - General and administrative expenses were reported at $113.5 million, a 29% increase compared to the previous year[1] - The company reported a net restructuring charge of $96 million, indicating ongoing strategic adjustments[1] - The company is focusing on strategic acquisitions and investments, with associated expenses of $474 million[1] - Future guidance indicates a continued emphasis on R&D, with expectations for further increases in development expenses[1] Cash Flow and Assets - Free cash flow for the quarter was $857,663,000, resulting in a free cash flow margin of approximately 66.8% of revenue[16] - Net cash provided by operating activities for the twelve months ended January 31, 2026, was $1,221,942 thousand, up from $959,764 thousand in the previous year, representing a 27.3% increase[29] - Cash and cash equivalents at the end of the period rose to $2,864,303 thousand, up from $2,698,678 thousand, indicating a 6.1% increase[29] - Total assets increased to $9,132,495 thousand as of January 31, 2026, compared to $9,033,938 thousand in the previous year, reflecting a growth of 1.1%[27] Strategic Focus - Snowflake aims to enhance its product offerings and market presence, particularly in AI and data cloud services, to drive future growth and customer engagement[19] - The company plans to expand its market presence through new product launches and technological advancements[1] - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[1] - Future guidance indicates a focus on strategic investments and acquisitions to drive growth[33] - The company plans to enhance its market expansion efforts in key regions[33] - New product development initiatives are underway, aimed at increasing market share[33]

Chime Reports Fourth Quarter and Full Year 2025 Financial Results 31% year-over-year revenue growth in full year 2025, exceeding guidance Scaled MyPay to over $400 million in revenue run rate and achieved 1% loss rate after one year Expects to achieve GAAP profitability in 2026 SAN FRANCISCO – (BUSINESS WIRE) – February 26, 2026 – Chime® (Nasdaq: CHYM), America's #1 Choice for Banking , today reported financial results for the quarter ended December 31, 2025. 1 "We delivered strong results in 2025, with 31% ...

Exhibit 99.1 agilon health Reports Fourth Quarter and Full Year Fiscal 2025 Results Issues 2026 Guidance Highlighting Expected Breakeven Adjusted EBITDA Midpoint Westerville, O.H., February 25, 2026 – agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the fourth quarter and fiscal year ended December 31, 2025. "2025 was a pivotal year for agilon. We confronted challenges head-on and focused our actions to accele ...